245 related articles for article (PubMed ID: 31506334)
1. Oncogenic KRAS Sensitizes Lung Adenocarcinoma to GSK-J4-Induced Metabolic and Oxidative Stress.
Hong BJ; Park WY; Kim HR; Moon JW; Lee HY; Park JH; Kim SK; Oh Y; Roe JS; Kim MY
Cancer Res; 2019 Nov; 79(22):5849-5859. PubMed ID: 31506334
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
3.
Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
[No Abstract] [Full Text] [Related]
4. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
5. The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol.
Albayrak G; Korkmaz FD; Tozcu D; Dogan Turacli I
J Cell Biochem; 2019 Jun; 120(6):10564-10571. PubMed ID: 30628735
[TBL] [Abstract][Full Text] [Related]
6. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.
Hu K; Li K; Lv J; Feng J; Chen J; Wu H; Cheng F; Jiang W; Wang J; Pei H; Chiao PJ; Cai Z; Chen Y; Liu M; Pang X
J Clin Invest; 2020 Apr; 130(4):1752-1766. PubMed ID: 31874110
[TBL] [Abstract][Full Text] [Related]
7. Novel activating KRAS mutation candidates in lung adenocarcinoma.
Abe J; Tanuma N; Nomura M; Ito S; Kasugai I; Sato I; Tamai K; Mochizuki M; Yamaguchi K; Shima H; Okada Y; Yasuda J
Biochem Biophys Res Commun; 2020 Feb; 522(3):690-696. PubMed ID: 31787238
[TBL] [Abstract][Full Text] [Related]
8. IκB Kinase α Is Required for Development and Progression of
Vreka M; Lilis I; Papageorgopoulou M; Giotopoulou GA; Lianou M; Giopanou I; Kanellakis NI; Spella M; Agalioti T; Armenis V; Goldmann T; Marwitz S; Yull FE; Blackwell TS; Pasparakis M; Marazioti A; Stathopoulos GT
Cancer Res; 2018 Jun; 78(11):2939-2951. PubMed ID: 29588349
[TBL] [Abstract][Full Text] [Related]
9. Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.
Lochmann TL; Powell KM; Ham J; Floros KV; Heisey DAR; Kurupi RIJ; Calbert ML; Ghotra MS; Greninger P; Dozmorov M; Gowda M; Souers AJ; Reynolds CP; Benes CH; Faber AC
Sci Transl Med; 2018 May; 10(441):. PubMed ID: 29769286
[TBL] [Abstract][Full Text] [Related]
10. The antischistosomal potential of GSK-J4, an H3K27 demethylase inhibitor: insights from molecular modeling, transcriptomics and in vitro assays.
Lobo-Silva J; Cabral FJ; Amaral MS; Miyasato PA; de Freitas RP; Pereira ASA; Khouri MI; Barbosa MMF; Ramos PIP; Leite LCC; Asojo OA; Nakano E; Verjovski-Almeida S; Farias LP
Parasit Vectors; 2020 Mar; 13(1):140. PubMed ID: 32178714
[TBL] [Abstract][Full Text] [Related]
11. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin.
Wang Q; Chen X; Jiang Y; Liu S; Liu H; Sun X; Zhang H; Liu Z; Tao Y; Li C; Hu Y; Liu D; Ye D; Liu Y; Wang M; Zhang X
J Mol Cell Biol; 2020 Feb; 12(2):125-137. PubMed ID: 31065671
[TBL] [Abstract][Full Text] [Related]
12. Histone demethylase UTX is a therapeutic target for diabetic kidney disease.
Chen H; Huang Y; Zhu X; Liu C; Yuan Y; Su H; Zhang C; Liu C; Xiong M; Qu Y; Yun P; Zheng L; Huang K
J Physiol; 2019 Mar; 597(6):1643-1660. PubMed ID: 30516825
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.
Mathur R; Sehgal L; Havranek O; Köhrer S; Khashab T; Jain N; Burger JA; Neelapu SS; Davis RE; Samaniego F
Haematologica; 2017 Feb; 102(2):373-380. PubMed ID: 27742770
[TBL] [Abstract][Full Text] [Related]
14. Effects of GSK-J4 on JMJD3 Histone Demethylase in Mouse Prostate Cancer Xenografts.
Sanchez A; Penault-Llorca F; Bignon YJ; Guy L; Bernard-Gallon D
Cancer Genomics Proteomics; 2022; 19(3):339-349. PubMed ID: 35430567
[TBL] [Abstract][Full Text] [Related]
15. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
16. GSK-J4: An H3K27 histone demethylase inhibitor, as a potential anti-cancer agent.
Dalpatraj N; Naik A; Thakur N
Int J Cancer; 2023 Sep; 153(6):1130-1138. PubMed ID: 37165737
[TBL] [Abstract][Full Text] [Related]
17. The histone demethylase inhibitor GSK-J4 limits inflammation through the induction of a tolerogenic phenotype on DCs.
Doñas C; Carrasco M; Fritz M; Prado C; Tejón G; Osorio-Barrios F; Manríquez V; Reyes P; Pacheco R; Bono MR; Loyola A; Rosemblatt M
J Autoimmun; 2016 Dec; 75():105-117. PubMed ID: 27528513
[TBL] [Abstract][Full Text] [Related]
18. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative effect of the histone demethylase inhibitor GSK-J4 in chondrosarcomas.
Lhuissier E; Aury-Landas J; Allas L; Boittin M; Boumediene K; Baugé C
IUBMB Life; 2019 Nov; 71(11):1711-1719. PubMed ID: 31241814
[TBL] [Abstract][Full Text] [Related]
20. Antitumoral Potential of the Histone Demethylase Inhibitor GSK-J4 in Retinoblastoma.
Zhang Y; Wu W; Xu C; Yang H; Huang G
Invest Ophthalmol Vis Sci; 2024 Feb; 65(2):34. PubMed ID: 38393716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
